Opendata, web and dolomites

ESPS SIGNED

Epileptic Seizure Prediction System (ESPS) - Predicting and preventing epileptic seizures based on respiratory biofeedback & machine learning.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ESPS project word cloud

Explore the words cloud of the ESPS project. It provides you a very rough idea of what is the project "ESPS" about.

esps    leave    70    pharmacological    independent    trials    boston    onset    healthcare    wearable    stress    cure    50m    caregiver    structured    people    harvard    injuries    preventive    visits    sent    pending    hesitant    literally    burden    shared    patient    alert    clinicians    reduces    decades    lives    clinical    risks    predicting    algorithm    personalized    business    detection    alone    learning    follow    majority    patients    intervention    despite    received    life    disrupts    machine    house    prone    innovation    caretaking    introduction    hard    methodology    week    desired    changed    ibreve    nature    seizure    reliably    time    seizures    plan    worldwide    patterns    drugs    pillars    unpredictable    personalize    causes    disrupt    obtain    probability    care    staggering    therapies    prediction    tracking    saving    nervous    introducing    entering    health    children    epilepsy    disorders    shift    hospital    treatment    patent    14    14b    analyzes    regulatory    clinician    employment    calculates    caused    homecare    elderly    antiepileptic    feasibility    reducing    intensity    respiratory    market    cycle   

Project "ESPS" data sheet

The following table provides information about the project.

Coordinator
IBREVE LIMITED 

Organization address
address: GROUND FLOOR 8-9 MARINO MART FAIRVIEW
city: DUBLIN
postcode: D03 P590
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.epilepsy.ibreve.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-07-01   to  2019-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IBREVE LIMITED IE (DUBLIN) coordinator 50˙000.00

Map

 Project objective

Epilepsy is one of the most common nervous system disorders and affects more than 50M people worldwide. The majority of new-onset cases occur in elderly and children. Currently there is no cure for epilepsy. Although antiepileptic drugs can help, one third of all patients do not respond to any pharmacological intervention. This staggering number has not changed in decades, despite over 14 new therapies entering the market. The unpredictable nature of seizures causes the largest burden for patients as it literally disrupts their lives. Patients with several seizures a week are hesitant to leave the house & find it hard to obtain employment. Reliably predicting seizures enables an independent life for the patient and at the same time reduces healthcare costs caused by clinician visits, injuries & caretaking. iBreve’s new patent-pending wearable technology analyzes respiratory patterns in real-time, enabling market applications for seizure prediction, respiratory treatment & stress management. iBreve’s technology received interest from Harvard’s Boston Children’s Hospital to be included in clinical trials for seizure detection & prediction. The ESPS machine learning algorithm calculates seizure probability & intensity and if desired an alert is sent to the patient’s caregiver. The tracking and analysis of seizures can be shared with clinicians & allows to personalize treatment. Main objective of this feasibility study is the development of a comprehensive business plan to evaluate the opportunities & risks of introducing ESPS into the homecare market. All project activities follow the Healthcare Innovation Cycle methodology & are structured around 4 development pillars - Technology, Market & Business, Clinical and Regulatory. The introduction of ESPS is prone to disrupt the epilepsy market by reducing treatment costs per patient by up to 70%. Thus, saving 14B€ in health care costs in Europe alone and creating a major shift towards preventive & personalized treatment.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ESPS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ESPS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

LIVELMIA (2019)

Innovative assay for microRNAs analysis

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More